

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

**In re:**

**PURDUE PHARMA L.P., et al.,  
  
Debtors. <sup>1</sup>**

**Chapter 11**

**Case No. 19-23649**

**(Jointly Administered)**

**DECHERT LLP'S FOURTH SUPPLEMENTAL DECLARATION  
PURSUANT TO BANKRUPTCY RULE 2014(A)**

I, Shmuel Vasser, hereby declare that the following statements are true and correct to the best of my knowledge after due inquiry as described herein:

1. I am a partner of the law firm of Dechert LLP ("**Dechert**"), which maintains offices at 1095 Avenue of the Americas, New York, New York 10036. I submit this declaration (the "**Fourth Supplemental Declaration**") to provide additional disclosure required under Rule 2014(a) of the Federal Rules of Bankruptcy Procedure (the "**Bankruptcy Rules**") of Dechert's connections with potential parties-in-interest in the Debtors' chapter 11 cases (the "**Chapter 11 Cases**").

2. This Fourth Supplemental Declaration supplements the disclosures provided in Dechert's prior supplemental declarations, [Docket Nos. 488, 683 and 817], and Hayden Coleman's declaration [Docket No. 424-2] filed contemporaneously with the *Application of*

---

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

*Debtors for Authority to Retain and Employ Dechert LLP as Special Counsel to the Debtors*

*Nunc Pro Tunc to the Petition Date* [Docket No. 424] (the “**Retention Application**”).<sup>2</sup> Except as otherwise noted, I have personal knowledge of the matters set forth herein, and if called and sworn as a witness, I could and would testify competently thereto.

3. Dechert and certain of its partners, counsel, and associates have recently been engaged to represent an entity or affiliates of an entity listed as a vendor on the conflict check list provided by the Debtors to Dechert, in a German regulatory inquiry. Dechert’s representation of this entity is not related to Dechert’s representation of the Debtors in the matters for which Dechert was retained in the Chapter 11 Cases.

4. Based upon the information available to me, Dechert neither represents nor holds an interest adverse to the interests of the Debtors or their estates with respect to the matters on which Dechert is to be employed.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct to the best of my information, knowledge and belief.

Date: February 20, 2020

/s/ Shmuel Vasser  
Shmuel Vasser

---

<sup>2</sup> Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Retention Application.